智通财经APP获悉，杰富瑞分析师David Windley将Icon PLC(ICLR.US)的评级从“买入”下调至“持有”，并将目标价从220美元下调至175美元。Windley目前认为Icon PLC面临的不利因素“过多”，因此不再推荐该股票，尽管该股票价格“低廉”，但可能还会再次下调业绩预期。
杰富瑞表示，渠道调查持续显示Icon PLC的钱包份额在流失，这削弱了自PRA Health 合并以来赢得四份合作协议所带来的发展势头。
杰富瑞还表示，第三季度客户取消订单金额可能接近10亿美元，而在第四季度这一数字可能仍会保持高位。
Icon PLC是一家临床研究机构，为生物技术、制药和医疗器械行业提供外包研发服务。该公司专注于管理、开发和分析临床开发相关项目。公司业务遍及爱尔兰、欧洲其他地区和美国等。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.